The effect of [18F]F-FAPI PET-CT on management in patients with potentially resectable biliary tract cancers: prospective multicenter study and cost-effectivity analysis.

Prior treatment

• Previous abdominal surgery

Other illness

• Known allergic reaction to therapeutic radiopharmaceuticals

Lab values

• Impaired renal function, defined as eGFR (MDRD) <25 ml/min/1,73 m2. An exception can be made in consultation with the treating physician.
• Any (other) condition, disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that may affect the interpretation of the results, or which might contribute substantially to the patient's experience of study burden (such as non-suppressible claustrophobia)

Other

• Patient had FDG PET-CT in addition to preoperative CT and MRI
• Contra-indication for performing PET-CT
• Indication for FDG PET-CT
• Pregnancy or lactation, for the latter, temporary discontinuation may be considered
• Inability to lie still on the back for the duration of PET-CT

• Patient is scheduled for explorative laparoscopy or laparotomy for suspicion of proximal cholangiocarcinoma (perihilar, intrahepatic and gall bladder cholangiocarcinoma)
• Tumor is regarded as resectable based on preoperative CT and MRI
• Patient is 18 years or older and is able to give informed consent